Each vial contains a stable population of 2 million Neuro-2a cells expressing the Incucyte® Nuclight Red fluorescent protein, restricted to the nucleus. Parental Neuro-2a cells were purchased from ATCC (Cat. No. CCL-131). Neuro-2a cells were transduced with the Incucyte® Nuclight Red Lentivirus (Cat. No. 4476; EF1α, puromycin). 48 hours post infection, the complete population of cells were grown for 3-5 days in complete growth media containing 2 µg/ml puromycin to select for cells expressing Incucyte® Nuclight Red. Incucyte® Nuclight Red expressing cells are maintained in complete media containing 0.5 µg/ml puromycin. Following selection, a panel of validation assays designed to evaluate the effects of nuclear label expression on functional cell biology was completed. These assays include comparisons of cell morphology, growth/proliferation, and neurite outgrowth between stable populations and the parent populations from which they were derived. In addition, all cells in our complete Incucyte® Nuclight catalog have been certified mycoplasma free by ATCC.